584 related articles for article (PubMed ID: 26946217)
1. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
Nishijima TF; Muss HB; Shachar SS; Moschos SJ
Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
3. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yan X; Tian X; Wu Z; Han W
Front Oncol; 2020; 10():1671. PubMed ID: 33072551
[No Abstract] [Full Text] [Related]
4. Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang L; Sun L; Yu J; Shan F; Zhang K; Pang X; Ma C; Zhang Y; Shen M; Ma S; Ruan S
Biomed Res Int; 2019; 2019():9853701. PubMed ID: 31214620
[TBL] [Abstract][Full Text] [Related]
5. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
[No Abstract] [Full Text] [Related]
6. The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis.
Li P; Yang X; Feng Y; Wu L; Ma W; Ding G; Wei Y; Sun L
Onco Targets Ther; 2018; 11():7521-7527. PubMed ID: 30464500
[TBL] [Abstract][Full Text] [Related]
7. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
[TBL] [Abstract][Full Text] [Related]
8. Correlation between patients' age and cancer immunotherapy efficacy.
Wu Q; Wang Q; Tang X; Xu R; Zhang L; Chen X; Xue Q; Wang Z; Shi R; Wang F; Ju F; Zhang B; Zhou YL
Oncoimmunology; 2019; 8(4):e1568810. PubMed ID: 30906662
[No Abstract] [Full Text] [Related]
9. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.
Kim CM; Lee JB; Shin SJ; Ahn JB; Lee M; Kim HS
ESMO Open; 2022 Oct; 7(5):100577. PubMed ID: 36156450
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.
Kim BJ; Kim JH; Kim HS
Oncotarget; 2017 Aug; 8(31):51779-51785. PubMed ID: 28881686
[TBL] [Abstract][Full Text] [Related]
12. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis.
Landre T; Des Guetz G; Chouahnia K; Fossey-Diaz V; Culine S
Drugs Aging; 2020 Oct; 37(10):747-754. PubMed ID: 32681403
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
15. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
17. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.
Corbaux P; Maillet D; Boespflug A; Locatelli-Sanchez M; Perier-Muzet M; Duruisseaux M; Kiakouama-Maleka L; Dalle S; Falandry C; Péron J
Eur J Cancer; 2019 Nov; 121():192-201. PubMed ID: 31590080
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma.
Zhao B; Zhao H; Zhao J
Int J Cancer; 2019 Jan; 144(1):169-177. PubMed ID: 30121946
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
[No Abstract] [Full Text] [Related]
[Next] [New Search]
